KR20240133712A - 장 펩티드의 폴리시스트론 발현 - Google Patents

장 펩티드의 폴리시스트론 발현 Download PDF

Info

Publication number
KR20240133712A
KR20240133712A KR1020247023274A KR20247023274A KR20240133712A KR 20240133712 A KR20240133712 A KR 20240133712A KR 1020247023274 A KR1020247023274 A KR 1020247023274A KR 20247023274 A KR20247023274 A KR 20247023274A KR 20240133712 A KR20240133712 A KR 20240133712A
Authority
KR
South Korea
Prior art keywords
peptide
seq
sequence
expression construct
chapter
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
KR1020247023274A
Other languages
English (en)
Korean (ko)
Inventor
쉬에퀴 궈
알렉산드리아 포브스
Original Assignee
메이라지티엑스 유케이 Ii 리미티드
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 메이라지티엑스 유케이 Ii 리미티드 filed Critical 메이라지티엑스 유케이 Ii 리미티드
Publication of KR20240133712A publication Critical patent/KR20240133712A/ko
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A61K48/005—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'active' part of the composition delivered, i.e. the nucleic acid delivered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4713—Autoimmune diseases, e.g. Insulin-dependent diabetes mellitus, multiple sclerosis, rheumathoid arthritis, systemic lupus erythematosus; Autoantigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C07K14/605—Glucagons
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/02—Fusion polypeptide containing a localisation/targetting motif containing a signal sequence
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/31—Fusion polypeptide fusions, other than Fc, for prolonged plasma life, e.g. albumin
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/50—Fusion polypeptide containing protease site
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2750/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA viruses
    • C12N2750/00011—Details
    • C12N2750/14011—Parvoviridae
    • C12N2750/14111—Dependovirus, e.g. adenoassociated viruses
    • C12N2750/14141—Use of virus, viral particle or viral elements as a vector
    • C12N2750/14143—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2800/00—Nucleic acids vectors
    • C12N2800/22—Vectors comprising a coding region that has been codon optimised for expression in a respective host
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2840/00—Vectors comprising a special translation-regulating system
    • C12N2840/20—Vectors comprising a special translation-regulating system translation of more than one cistron

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Diabetes (AREA)
  • Zoology (AREA)
  • Medicinal Chemistry (AREA)
  • Biotechnology (AREA)
  • Molecular Biology (AREA)
  • Wood Science & Technology (AREA)
  • Biophysics (AREA)
  • Biomedical Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Endocrinology (AREA)
  • Hematology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Obesity (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Plant Pathology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Toxicology (AREA)
  • Microbiology (AREA)
  • Physics & Mathematics (AREA)
  • Emergency Medicine (AREA)
  • Virology (AREA)
  • Epidemiology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Immunology (AREA)
  • Rehabilitation Therapy (AREA)
KR1020247023274A 2021-12-15 2022-12-15 장 펩티드의 폴리시스트론 발현 Pending KR20240133712A (ko)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202163361399P 2021-12-15 2021-12-15
US63/361,399 2021-12-15
PCT/IB2022/000815 WO2023131811A2 (en) 2021-12-15 2022-12-15 Polycistronic expression of gut peptides

Publications (1)

Publication Number Publication Date
KR20240133712A true KR20240133712A (ko) 2024-09-04

Family

ID=86732042

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020247023274A Pending KR20240133712A (ko) 2021-12-15 2022-12-15 장 펩티드의 폴리시스트론 발현

Country Status (10)

Country Link
US (1) US20250302992A1 (cg-RX-API-DMAC7.html)
EP (1) EP4448555A2 (cg-RX-API-DMAC7.html)
JP (1) JP2025500874A (cg-RX-API-DMAC7.html)
KR (1) KR20240133712A (cg-RX-API-DMAC7.html)
CN (1) CN118434758A (cg-RX-API-DMAC7.html)
AU (1) AU2022431978B2 (cg-RX-API-DMAC7.html)
CA (1) CA3239128A1 (cg-RX-API-DMAC7.html)
IL (1) IL313462A (cg-RX-API-DMAC7.html)
MX (1) MX2024007519A (cg-RX-API-DMAC7.html)
WO (1) WO2023131811A2 (cg-RX-API-DMAC7.html)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2026092369A1 (zh) * 2024-10-31 2026-05-07 派格生物医药(杭州)股份有限公司 一种环状rna分子及其应用
US20260174836A1 (en) * 2024-12-20 2026-06-25 Wyvern Pharmaceuticals Inc. Composition for regulating production of proteins

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2346262A1 (en) 1998-09-17 2000-03-23 University Of Florida Methods for treatment of degenerative retinal diseases
EP1572885A2 (en) * 2001-08-08 2005-09-14 Genzyme Corporation Methods for treating diabetes and other blood sugar disorders
EP1799825B1 (en) * 2004-10-05 2011-06-29 The California Institute of Technology Aptamer regulated nucleic acids and uses thereof
US7829664B2 (en) * 2007-06-01 2010-11-09 Boehringer Ingelheim International Gmbh Modified nucleotide sequence encoding glucagon-like peptide-1 (GLP-1), nucleic acid construct comprising same for production of glucagon-like peptide-1 (GLP-1), human cells comprising said construct and insulin-producing constructs, and methods of use thereof
WO2016126747A1 (en) 2015-02-02 2016-08-11 Meiragtx Uk Limited Regulation of gene expression by aptamer-mediated modulation of alternative splicing
MY198399A (en) 2016-02-02 2023-08-28 Meiragtx Uk Ii Ltd Regulation of gene expression via aptamer-mediated control of self-cleaving ribozymes
PH12018501650B1 (en) 2016-02-02 2024-07-03 Meiragtx Uk Ii Ltd Regulation of gene expression through aptamer-modulated polyadenylation
US11311633B2 (en) * 2016-04-16 2022-04-26 University Of Florida Research Foundation, Incorporated Satiation peptides for weight loss and altered taste sensitivity
MA44546B1 (fr) 2016-06-15 2021-03-31 Univ California Virus adéno-associés variants et procédés d'utilisation
SG11201907700XA (en) 2017-02-21 2019-09-27 Meiragtx Uk Ii Limited Regulation of gene expression by aptamer-mediated accessibility of polyadenylation signals
CA3055100A1 (en) 2017-03-02 2018-09-07 MEIRAGTX, UK II Limited Regulation of gene expression by aptamer-modulated rnase p cleavage

Also Published As

Publication number Publication date
WO2023131811A2 (en) 2023-07-13
IL313462A (en) 2024-08-01
JP2025500874A (ja) 2025-01-15
US20250302992A1 (en) 2025-10-02
WO2023131811A3 (en) 2023-09-14
AU2022431978A1 (en) 2024-07-11
CN118434758A (zh) 2024-08-02
CA3239128A1 (en) 2023-07-13
EP4448555A2 (en) 2024-10-23
MX2024007519A (es) 2024-08-28
AU2022431978B2 (en) 2026-05-07

Similar Documents

Publication Publication Date Title
US12416018B2 (en) Regulation of gene expression by aptamer-mediated modulation of alternative splicing
US20230220382A1 (en) Regulation of gene expression via aptamer-mediated control of self-cleaving ribozymes
AU2022431978B2 (en) Polycistronic expression of gut peptides
AU2021332235A1 (en) Viral vectors encoding GLP-1 receptor agonist fusions and uses thereof in treating metabolic diseases
US20250171515A1 (en) Aav vectors for delivery of glp-1 receptor agonist fusions
IL298178A (en) Compositions useful for treatment of pompe disease
US20250186613A1 (en) Viral vectors encoding glp-2 receptor agonist fusions and uses thereof in treating short bowel syndrome
Owen IV et al. Approaches and limitations to gene therapy for mitochondrial diseases
HK40059892A (en) Regulation of gene expression by aptamer-mediated modulation of alternative splicing
JP2025504910A (ja) 心臓形質導入の改善及び肝臓の脱標的化のためのaavカプシド
HK40001466A (en) Regulation of gene expression via aptamer-mediated control of self-cleaving ribozymes
HK40001466B (en) Regulation of gene expression via aptamer-mediated control of self-cleaving ribozymes
HK1248760B (en) Regulation of gene expression by aptamer-mediated modulation of alternative splicing

Legal Events

Date Code Title Description
PA0105 International application

St.27 status event code: A-0-1-A10-A15-nap-PA0105

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

PG1501 Laying open of application

St.27 status event code: A-1-1-Q10-Q12-nap-PG1501

PN2301 Change of applicant

St.27 status event code: A-3-3-R10-R11-asn-PN2301

R11 Change to the name of applicant or owner or transfer of ownership requested

Free format text: ST27 STATUS EVENT CODE: A-3-3-R10-R11-ASN-PN2301 (AS PROVIDED BY THE NATIONAL OFFICE)

E13 Pre-grant limitation requested

Free format text: ST27 STATUS EVENT CODE: A-2-3-E10-E13-LIM-X000 (AS PROVIDED BY THE NATIONAL OFFICE)

E13-X000 Pre-grant limitation requested

St.27 status event code: A-2-3-E10-E13-lim-X000

P11 Amendment of application requested

Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P11-NAP-X000 (AS PROVIDED BY THE NATIONAL OFFICE)

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000